Anbio Biotechnology (NASDAQ:NNNN) Sees Significant Decrease in Short Interest

Anbio Biotechnology (NASDAQ:NNNN) was the target of a large drop in short interest in the month of July. As of July 15th, there was short interest totaling 31,583 shares, a drop of 64.6% from the June 30th total of 89,295 shares. Approximately 0.0% of the company’s stock are short sold. Based on an average daily volume of 42,616 shares, the short-interest ratio is currently 0.7 days.

Analyst Ratings Changes

Separately, Weiss Ratings raised shares of Anbio Biotechnology from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, May 14th. One research analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, the company has a consensus rating of “Hold”.

Anbio Biotechnology Trading Down 0.3%

Shares of NASDAQ:NNNN traded down $0.03 on Tuesday, reaching $10.15. The company had a trading volume of 30,499 shares, compared to its average volume of 43,915. Anbio Biotechnology has a 52-week low of $8.30 and a 52-week high of $54.95. The business has a 50 day moving average of $18.07.

About Anbio Biotechnology

Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. Our unwavering commitment lies in transforming the diagnostics landscape on a global scale, fostering a paradigm shift towards personalized and decentralized diagnostic solutions. By doing so, we aim to significantly enhance patient prognosis and contribute to the betterment of healthcare worldwide. At Anbio Biotechnology, our extensive portfolio comprises an array of IVD products designed to cater to diverse diagnostic needs.